Medical Oncology, Год журнала: 2022, Номер 39(9)
Опубликована: Июнь 18, 2022
Язык: Английский
Cancers, Год журнала: 2022, Номер 14(16), С. 4059 - 4059
Опубликована: Авг. 22, 2022
With 400,000 diagnosed and 180,000 deaths in 2020, renal cell carcinoma (RCC) accounts for 2.4% of all cancer diagnoses worldwide. The highest disease burden developed countries, primarily Europe North America. Incidence is projected to increase the future as more countries shift Western lifestyles. Risk factors RCC include fixed such gender, age, hereditary diseases, well intervening smoking, obesity, hypertension, diabetes, diet alcohol, occupational exposure. Intervening primary prevention, understanding congenital risk establishment early diagnostic tools are important RCC. This review will discuss epidemiology, factors, biomarkers involved reducing incidence improving survival.
Язык: Английский
Процитировано
76
Small, Год журнала: 2024, Номер 20(35)
Опубликована: Май 1, 2024
Abstract Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art nanovaccine development, elucidating innovative strategies and technologies employed their design. It explores both preclinical clinical advancements, emphasizing key studies demonstrating potential elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, impact of nanoscale properties on performance. Detailed insights into complex interplay between tumor microenvironment responses are provided, highlighting challenges opportunities optimizing therapeutic outcomes. Additionally, presents thorough analysis ongoing trials, presenting snapshot landscape. By curating latest scientific findings developments, this aims serve as comprehensive resource researchers clinicians engaged advancing immunotherapy. Integrating design holds immense promise revolutionizing treatment paradigms, provides timely update evolving landscape nanovaccines.
Язык: Английский
Процитировано
24
Journal of Biochemical and Molecular Toxicology, Год журнала: 2021, Номер 35(11)
Опубликована: Авг. 31, 2021
Abstract Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are strategies for addressing tumors raised solid organs including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, combinational stem cell extracellular vesicle (EV) therapy. Surgery, chemotherapy the dominant cures, but not always effective, in which even localized tumor there is possibility relapse after surgical resection. Over half patients will receive radiotherapy as part their therapeutic schedule. Radiotherapy can cause an abscopal response boosting activity immune system outside local field radiation, it may also unwanted bystander effect, predisposing nonradiated cells into carcinogenesis. In context checkpoint inhibition known standard‐of‐care, major concern regard with cold that show low responses to such Stem‐cell therapy be used send prodrugs toward area; this strategy, however, has its own predicaments, attraction other sites healthy tissues instability. A substitute quite novel strategy use EVs, by virtue stability potential cross biological barriers long‐term storage contents. Combination current focus. Despite advances field, still unmet concerns area effective raising challenges opportunities future investigations.
Язык: Английский
Процитировано
93
Life Sciences, Год журнала: 2021, Номер 286, С. 120057 - 120057
Опубликована: Окт. 18, 2021
Язык: Английский
Процитировано
70
Biomedicine & Pharmacotherapy, Год журнала: 2021, Номер 145, С. 112419 - 112419
Опубликована: Ноя. 12, 2021
Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High concentration of this pleiotropic accounts for hyperinflammation storm, related to multi-organ failure SARS-CoV-2 induced disease. IL-6 promotes lymphopenia increases C-reactive protein (CRP) such cases. However, blockade not full-proof complete response. Hypoxia, hypoxemia, aberrant angiogenesis chronic inflammation are inter-related events occurring as response the stimulatory effect on activity. Taking both pro- anti-inflammatory activities will make complex targeting patient The aim review was discuss about interactions within body disease who representing levels, determine whether inhibition therapy effective or not. We also address targeted therapies cancer have
Язык: Английский
Процитировано
57
Seminars in Cancer Biology, Год журнала: 2022, Номер 86, С. 860 - 872
Опубликована: Фев. 1, 2022
Язык: Английский
Процитировано
56
Cancer Medicine, Год журнала: 2022, Номер 11(15), С. 2934 - 2943
Опубликована: Март 17, 2022
Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised area, as recent studies showed that such therapeutic modality suffers from low durability and or no efficacy for patients with some tumor types including cases non-inflamed cold cancers. Therefore, efforts have been made to solve issue combination therapy, use of immunocytokines. The ICI interleukins (ILs) IL-targeting agents now under consideration area primary results promising. this review discuss possibility ILs drugs immunotherapy describing advances field PEGylated fusion proteins. key reduce adverse events increase therapy.
Язык: Английский
Процитировано
40
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Ноя. 2, 2023
Natural killer (NK) cells kill mutant through death receptors and cytotoxic granules, playing an essential role in controlling cancer progression. However, the tumor microenvironment (TME), NK frequently exhibit exhausted status, which impairs their immunosurveillance function contributes to immune evasion. Emerging studies are ongoing reveal properties mechanisms of cell exhaustion TME. In this review, we will briefly introduce maturation, localization, homeostasis, cytotoxicity cells. We then summarize current understanding main underlying TME four aspects: dysregulation inhibitory activating signaling, cell-derived factors, immunosuppressive cells, metabolism exhaustion. also discuss therapeutic approaches currently being developed reverse enhance
Язык: Английский
Процитировано
38
Pathology - Research and Practice, Год журнала: 2024, Номер 254, С. 155120 - 155120
Опубликована: Янв. 11, 2024
Язык: Английский
Процитировано
11
Cellular Oncology, Год журнала: 2022, Номер 45(3), С. 333 - 353
Опубликована: Май 19, 2022
Язык: Английский
Процитировано
38